Patents Assigned to Bitop AG
-
Publication number: 20230226056Abstract: The present invention relates to the use of organic and highly water-soluble compatible solutes or a solute mixture, preferably in the form of an inhalable, oropharyngeally, nasally and intravenously administrable composition, in the prevention or treatment of diseases caused by ss(+)RNA viruses of the Coronavriridae family, preferably of those diseases caused by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63 and/or HCoV-229E. Particularly suitable solutes in the meaning of the invention are ectoine and its derivatives, Glycoin, mannosylglycerate (Firoin) and mannosylglyceramide (Firoin-A), which, due to their strong water-binding capacity, reduce the binding of the viruses to the receptors of the host cell in the transitional epithelium, e.g. eye, in the internal epithelium, e.g. lung, and in the endothelium and thus reduce or prevent the multiplication of the viruses.Type: ApplicationFiled: May 10, 2021Publication date: July 20, 2023Applicant: bitop AGInventors: Thomas SCHWARZ, Eva GALIK, Dieter OESTERHELT
-
Publication number: 20220133719Abstract: The invention relates to a composition containing, as active ingredient, ectoine, hydroxyectoine and/or salts, esters or amides of these compounds for the treatment and/or prophylaxis of diseases of the eye that are associated with a disturbance of the tear film. The disease can be in particular a keratoconjunctivitis sicca. It has been found that, surprisingly, these compounds are capable of preventing a rupture in the outer lipid layer of the tear film, avoiding an undesirably rapid evaporation of the lacrimal fluid.Type: ApplicationFiled: August 5, 2021Publication date: May 5, 2022Applicant: BITOP AGInventors: Andreas Bilstein, Hans-Joachim Galla, Mridula Dwivedi
-
Publication number: 20210213039Abstract: The invention relates to a composition containing as active agent ectoine, hydroxyectoine, glucosylglycerol and/or salts, esters or amides of these compounds for promoting the regeneration of injured body tissue. The invention has special significance for the treatment of chronic wounds or ulcers.Type: ApplicationFiled: March 31, 2021Publication date: July 15, 2021Applicant: Bitop AGInventors: Andreas Bilstein, Olaf Scherner, Georg Lentzen
-
Publication number: 20210147889Abstract: A method for increased and permanent production of a natural compound by a microorganism during an exponential growth and during a stationary phase of a culture of the microorganism, the method comprising: enhancing a translation of a target mRNA, wherein the target mRNA comprises a transcript of a target gene, wherein the target gene is encoding the natural compound or a key enzyme involved in a biosynthesis of the natural compound in the microorganism, by replacing a wild type (wt) ribosome binding site (RBS) upstream of the target gene with a synthetic RBS, the synthetic RBS possessing a higher affinity towards a 16S rRNA of a ribosome of the microorganism than the wt RBS; and enhancing a transcription of the target gene by converting an osmotically regulated ?38 promoter upstream of the target gene into a stationary ?38 promoter, wherein the osmotically regulated ?38 promoter comprises a ?35 G-element and a ?10 element which are separated from each other by a spacer sequence, by deleting the ?35 G elemType: ApplicationFiled: March 1, 2018Publication date: May 20, 2021Applicants: Bundesrepublik Deutschland, Vertreten Durch Die Bundesministerin Für Wirtschaft Und Energie, bitop AGInventors: Hans Jörg Kunte, Gabriela Alfaro Espinoza, Andreas Bilstein
-
Publication number: 20200179380Abstract: The invention relates to a compatible solute or a solute mixture, as well as to a composition comprising the solute or solute mixture, for use in the prevention or treatment of cosmetic or pathologic efflorescences caused by airborne particles, such as pigmentation accompanying with skin ageing, and de- or hypopigmentation, hyperpigmentation, as well as alterations accompanying with atrophy in the broadest sense.Type: ApplicationFiled: February 7, 2020Publication date: June 11, 2020Applicant: bitop AGInventors: Andreas Bilstein, Jean Krutmann
-
Publication number: 20190380985Abstract: The invention relates to a composition containing N-acetyldiaminobutyric acid, a salt or an ester of N-acetyldiaminobutyric acid for application in a method for the treatment of the human or animal body.Type: ApplicationFiled: December 22, 2017Publication date: December 19, 2019Applicant: bitop AGInventor: Andreas Bilstein
-
Publication number: 20190350930Abstract: The invention relates to a composition containing as active agent ectoine, hydroxyectoine and/or salts, esters or amides of these compounds for use in a method for the treatment and/or prophylaxis of gastroesophageal reflux diseases, inflammation of and damage to the gastric or duodenal mucosa and/or of gastric or duodenal ulcers.Type: ApplicationFiled: June 27, 2017Publication date: November 21, 2019Applicant: bitop AGInventor: Andreas Bilstein
-
Publication number: 20190117651Abstract: The invention relates to a composition containing as active agent ectoine, hydroxyectoine and/or salts, esters or amides of these compounds for the stimulation of sirtuin activity, in particular for the treatment of diseases that are associated with reduced activity of sirtuins. These include in particular various aging phenomena and diseases that occur primarily in old age or are associated with an impaired cell differentiation or cell proliferation.Type: ApplicationFiled: March 13, 2017Publication date: April 25, 2019Applicant: Bitop AGInventors: Andreas BILSTEIN, Jean KRUTMANN, Klaus UNFRIED
-
Publication number: 20180353505Abstract: The invention relates to a compatible solute or a solute mixture as well as to a composition comprising at least one solute or one solute mixture for use in the prevention or treatment of barrier malfunctions of epithelial tissues associated with at least one biobased noxa, in particular of diseases comprising at least one barrier malfunction in at least one cell layer of at least one epithelial tissue, wherein at least one solute is selected from compounds of formula I, of formula II, physiologically compatible salts of formula I, formula II, stereoisomeric forms of the compounds of formula I, formula II, and physiologically compatible salts of the stereoisomeric forms, or a mixture of at least two of the afore-mentioned compounds. The at least one compatible solute, solute mixture and/or the compositions are provided in the form of a cosmetic, medical product, medicament, of an additive to one of the afore-mentioned products or as component of an in-vitro diagnostic product (IVD).Type: ApplicationFiled: December 2, 2016Publication date: December 13, 2018Applicant: bitop AGInventors: Andreas Bilstein, Olaf Scherner
-
Publication number: 20180015017Abstract: The invention relates to the use of glucosylglycerol or glucosylglycerol esters with a view to increasing the expression of cell protective enzymes for the protection and stabilization of human skin and/or mucous membranes. It has been demonstrated that glucosylglycerol plays an effective role in the stimulation and activation of cell protective enzymes such as superoxide dismutase. It is thus possible in this manner to protect human skin cells effectively against damaging external influences.Type: ApplicationFiled: September 27, 2017Publication date: January 18, 2018Applicant: Bitop AGInventors: Julia Kruger, Gerhard Stumm
-
Patent number: 9867767Abstract: The invention relates to the use of glucosylglycerol or glucosylglycerol esters with a view to increasing the expression of cell protective enzymes for the protection and stabilization of human skin and/or mucous membranes. It has been demonstrated that glucosylglycerol plays an effective role in the stimulation and activation of cell protective enzymes such as superoxide dismutase. It is thus possible in this manner to protect human skin cells effectively against damaging external influences.Type: GrantFiled: August 21, 2009Date of Patent: January 16, 2018Assignee: Bitop AGInventors: Julia Klein, Gerhard Stumm
-
Publication number: 20170202835Abstract: Osmolyte-containing preparations are provided for the local treatment of dry mucous membranes by enhancing mucus production. Included are the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. Topical preparations based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), ?-mannosylglycerate (Firoin), ?-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g., an acid, salt or ester, of these compounds.Type: ApplicationFiled: April 3, 2017Publication date: July 20, 2017Applicant: Bitop AGInventor: Hans Bernd Schmittmann
-
Publication number: 20170189435Abstract: The invention relates to a composition containing as active agent ectoine, hydroxyectoine, glucosylglycerol and/or salts, esters or amides of these compounds for promoting the regeneration of injured body tissue. The invention has special significance for the treatment of chronic wounds or ulcers.Type: ApplicationFiled: March 24, 2017Publication date: July 6, 2017Applicant: bitop AGInventors: Andreas Bilstein, Olaf Scherner, Georg Lentzen
-
Publication number: 20170173012Abstract: The invention relates to a composition containing, as active ingredient, ectoine, hydroxyectoine and/or salts, esters or amides of these compounds for the treatment and/or prophylaxis of diseases of the eye that are associated with a disturbance of the tear film. The disease can be in particular a keratoconjunctivitis sicca. It has been found that, surprisingly, these compounds are capable of preventing a rupture in the outer lipid layer of the tear film, avoiding an undesirably rapid evaporation of the lacrimal fluid.Type: ApplicationFiled: May 22, 2015Publication date: June 22, 2017Applicant: BITOP AGInventors: Andreas Bilstein, Hans-Joachim Galla, Mridula Dwivedi
-
Publication number: 20160106747Abstract: A method of treatment of a patient suffering from postoperative inflammatory stress and pain caused by mechanical impact exerted on portions of the body of the patient that causes damaged tissue wherein the inflammatory stress and pain of the operation outlast the healing of damaged tissue and which is not related to, or caused by, uncontrolled proteolysis. The treatment comprises administering a tetrahydropyrimidine selected from ectoine and/or hydroxyectoine to the patient.Type: ApplicationFiled: December 28, 2015Publication date: April 21, 2016Applicant: Bitop AGInventors: Rene Tolba, Gerhild van Echten-Deckert, Georg Lentzen, Andreas Bilstein
-
Publication number: 20150320747Abstract: The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes proposed by the invention embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), ?-mannosylglycerate (Firoin), ?-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g. an acid, salt or ester, of these compounds.Type: ApplicationFiled: September 24, 2012Publication date: November 12, 2015Applicant: Bitop AGInventor: Hans Bernd Schmittmann
-
Patent number: 9089568Abstract: The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), ?-mannosylglycerate (firoin), ?-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal diseases, with agents containing said active ingredients being disclosed as well.Type: GrantFiled: March 13, 2006Date of Patent: July 28, 2015Assignee: Bitop AGInventors: Thomas Schwarz, Georg Lentzen, Jean Krutmann
-
Publication number: 20150104781Abstract: The invention relates to a storage solution for the preservation of organs, tissue or organ systems to be transplanted, said solution being based on the known HTK, UW or Celsior solutions. In accordance with the invention it has been determined that ischemia and reperfusion injury could be reduced through the addition of ectoine or hydroxyectoine.Type: ApplicationFiled: March 15, 2013Publication date: April 16, 2015Applicant: bitop AGInventors: Andreas Bilstein, Georg Lentzen, Rene Tolba, Fabian Bernal Quesnel
-
Patent number: 8822477Abstract: The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis.Type: GrantFiled: July 1, 2004Date of Patent: September 2, 2014Assignee: Bitop AGInventor: Jean Krutmann
-
Patent number: 8765691Abstract: The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes used in the invention comprises various low-molecular substances, more specifically ectoine, 4,5,6,7-tetrahydro-2-methyl-1H-[1,3]-diazepine-4-S-carboxylic acid (homoectoine), hydroxyectoine, di-myo-inositol-phosphate (DIP), to cyclic 2,3-diphosphoglycerate (cDPG), 1,1-diglycerol phosphate (DGP), ?-mannosylglycerate (firoin), ?-mannosylglyceramide (firoin-A), dimannosyl-diinositol phosphate (DMIP), glucosylglycerol, taurine, betaine, citrulline, and/or a derivative, e.g. an acid, salt, or ester of said compounds.Type: GrantFiled: August 25, 2008Date of Patent: July 1, 2014Assignee: Bitop AGInventors: Jean Krutmann, Georg Lentzen, Thomas Schwarz